Holen Sie sich die Stockscreener-App
23.67
1.07%
0.2372
Schlusskurs vom Vortag:
$23.43
Offen:
$23.41
24-Stunden-Volumen:
79,048
Relative Volume:
0.07
Marktkapitalisierung:
$2.98B
Einnahmen:
$236.00M
Nettoeinkommen (Verlust:
$-369.00M
KGV:
-7.436
EPS:
-3.1828
Netto-Cashflow:
$-489.00M
1W Leistung:
+4.09%
1M Leistung:
-7.13%
6M Leistung:
-7.35%
1J Leistung:
+162.54%
1-Tages-Spanne:
$23.07
$23.84
1-Wochen-Bereich:
$23.02
$24.34
52-Wochen-Spanne:
$7.91
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
23.68 | 2.95B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
435.83 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.37 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.96 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.12 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences (RCUS) Insider Trading Activity 2026 - MarketBeat
RCUS Assumes Buy by Truist Securities -- Price Target Raised to $35 - GuruFocus
Arcus Biosciences Coverage Assumed by Truist Securities at Buy - Moomoo
Truist assumes Arcus Biosciences stock with buy on RCC potential By Investing.com - Investing.com Canada
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21% - Sahm
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Finance
Why (RCUS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Top Arcus Biosciences (RCUS) Competitors 2026 - MarketBeat
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock By Investing.com - Investing.com Canada
Arcus Biosciences CFO Robert Goeltz sells $198,965 in stock - Investing.com
Arcus (NYSE: RCUS) director gifts 5,050 shares in estate move - Stock Titan
Arcus Biosciences (RCUS) CFO logs 7,763-share Rule 10b5-1 sale - Stock Titan
Arcus Biosciences stock (US75626R1077): Form 144 filing signals insider RSU sales - AD HOC NEWS
TradingKey - TradingKey
Arcus Biosciences (RCUS) Form 144: Brokered notice for RSU sales via Merrill Lynch - Stock Titan
RCUS Maintained by Morgan Stanley -- Price Target Raised to $22 - GuruFocus
Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips - Investing.com Nigeria
Earnings call transcript: Arcus Biosciences misses Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa
Arcus Biosciences Q1 Loss Of US$128 Million Reinforces Bearish Profitability Concerns - Sahm
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Goldman Sachs Remains a Buy on Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Goldman Sachs -- Price Target Raised to $34 - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
MSN Money - MSN
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
RCUS (RCUS) Rule 144: Issuer sells 77,793 shares via option exercise - Stock Titan
Arcus Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:RCUS) 2026-05-06 - Seeking Alpha
Arcus Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift - Yahoo Finance
Arcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028 - MSN
Arcus Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
8-K: Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Updatemoomoo - Moomoo
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations By Investing.com - Investing.com Nigeria
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88 - marketscreener.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):